After gastric cancer surgery, according to the type of postoperative pathology and patient’s specific situation, targeted drug treatment is adopted. Clinically, targeted drugs include two commonly used categories, which are trastuzumab and apatinib. Trastuzumab is mainly applicable to some patients, and Apatinib is the targeted drug that acts on blood vessels to support tumor growth, which is more widely used and has more ideal effect, and the specific medication should be combined with the patient’s condition, pathological stage and the specific conditions of the body to decide together. After gastric cancer surgery, the application of targeted drugs should also be reviewed regularly, because some targeted drugs may have drug resistance. If drug resistance occurs, it is necessary to adjust the medication in time and replace other types of targeted drugs, which can more effectively inhibit the metastasis and recurrence of gastric cancer patients after surgery, and is conducive to the stabilization of the condition.